Skip to content

Inspection Record

Zydus Lifesciences Limited — FDA 483 Findings

US FDAInspected 2025-09-05Published 2026-02-13 4 findingsAseptic processing and sterility assuranceDeviation, CAPA, and investigationEnvironmental monitoring

View the regulator's official source The source document is always the basis for judgement.

Findings

1Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equipment to produce aseptic conditions.

2Deviation, CAPA, and investigation

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components lo meet any of its specifications whether or not the batch has been already distributed.

3Environmental monitoring

The responsibilities and procedures applicable to the quality control unitare not fully followed, Specifically, Your Quality Unit thiled to establish controls whieh prevents environmental monitoring data from being manipulated in the MODA-EM system, ‘This system is wilized by your taellily to document all environmental monitoring data including but not limited to surface sample monitoring, surtice sample swabbing, active air monitoring, and passive air monitoring [rom the filling tines, filling suiles, personnel monitoring, and finished product microbial analyses.

4Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-02-13. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Other records for this company

Zydus Lifesciences Limited findings history — including this company's other documentsAll US FDA findings US FDA documents, 2026 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.